Sareum Holdings Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	8.5yrs

Recente managementupdates

Recent updates

CEO

Sareum Holdings heeft geen CEO, of we hebben geen gegevens over hen.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Parker	Executive Chairman	8.5yrs	UK£92.87k	0.26% € 107.7k
John Reader	Founder	20.8yrs	UK£205.80k	1.04% € 435.8k
Timothy Mitchell	Founder & Executive Director	20.8yrs	UK£207.85k	1.05% € 437.6k
Clive H. Birch	Senior Independent Non-Executive Director & Secretary	6yrs	UK£25.00k	0.095% € 39.8k
Michael Owen	Independent Non-Executive Director	6yrs	UK£20.00k	0.0088% € 3.7k

8.5yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RYH0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.5 jaar).

Sareum Holdings Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Sareum Holdings plc Announces Board and Executive Changes

Sareum Holdings plc, Annual General Meeting, Dec 14, 2023

Insufficient new directors

Sareum Holdings plc, Annual General Meeting, Dec 16, 2022

Insufficient new directors

Insufficient new directors

Recent updates

Sareum Holdings plc to Report Fiscal Year 2024 Results on Oct 29, 2024

Sareum Holdings plc has completed a Follow-on Equity Offering in the amount of £1 million.

New minor risk - Financial data availability

Sareum Holdings plc Receives Notice of Allowance from the China National Intellectual Property Administration

Sareum Holdings plc Receives A Notice of Allowance from the US Patent and Trademark Office for A Patent on SDC-1801

Sareum Holdings plc Announces Board and Executive Changes

Sareum Holdings plc Announces Positive Data from SDC-1801 Phase 1 Clinical Trial

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Sareum Holdings plc has completed a Follow-on Equity Offering in the amount of £1.268973 million.

Sareum Holdings plc has completed a Follow-on Equity Offering in the amount of £1.268973 million.

Sareum Holdings plc has filed a Follow-on Equity Offering in the amount of £0.1875 million.

New major risk - Market cap size

Forecast to breakeven in 2026

New major risk - Share price stability

Sareum Holdings plc Announces Completion of the Single Ascending Dose (SAD) Part and the Food Effect Study of its Phase 1a Clinical Trial for the Lead Programme SDC-1801

Sareum Holdings plc Provides Update on Operational Activities and Pipeline Progress

Sareum Holdings plc, Annual General Meeting, Dec 14, 2023

Sareum Holdings plc Initiates Food Effects Study in Phase 1a Trial for SDC-1801

New minor risk - Insider selling

New minor risk - Shareholder dilution

Insufficient new directors

New minor risk - Financial data availability

Sareum Holdings plc to Report Fiscal Year 2023 Results on Oct 09, 2023

Sareum Holdings plc Starts Dosing First Subjects in the Multiple Ascending Dose Part of Phase 1a Clinical Trial for SDC-1801

Sareum Holdings plc Provides Earnings Guidance for the Year to 30 June 2023

New minor risk - Market cap size

Sareum Holdings plc Announces the Commencement of A Phase 1a Clinical Trial for SDC-1801

Sareum Holdings plc, Annual General Meeting, Dec 16, 2022

Insufficient new directors

Sareum Holdings plc Notes Publication of SRA737 Clinical Data

Sareum Holdings plc Notes FDA Approval of First TYK2 Inhibitor

Sareum Submits Clinical Trial Authorisation Application to UK MHRA for Development of TYK2/JAK1 Inhibitor SDC-1801

Sareum Holdings plc Provides Consolidated Sales Guidance for the Fiscal Year 2022

Insufficient new directors

Insufficient new directors

Sareum Holdings plc Announces European Patent Granted for Sareum’s SDC-1802

Insufficient new directors

CEO

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd